CJC-1295 with Ipamorelin (10 mg)

CJC-1295 and Ipamorelin are peptide compounds frequently utilized in academic and pharmaceutical research to investigate growth hormone and growth hormone-releasing hormone (GHRH) pathways. This product combines CJC-1295, a modified somatostatin analog, with Ipamorelin, a selective GHRH agonist, in a single formulation for enhanced experimental applications. Below is a detailed overview of the research context and applications associated with these compounds.

Research Context

Both CJC-1295 and Ipamorelin are synthetic peptides designed to modulate endogenous growth hormone (GH) secretion. CJC-1295 acts as a potent, long-acting antagonist of somatostatin receptors, thereby increasing GH release. Ipamorelin, conversely, selectively stimulates the pituitary gland to release GH via activation of GHRH receptors. Together, these peptides are studied in preclinical research to evaluate their potential effects on tissue regeneration, metabolic processes, and aging mechanisms.

Research Overview

Preclinical studies employing these peptides often explore their roles in enhancing tissue repair, modulating immune responses, and investigating age-related decline in growth hormone function. CJC-1295 and Ipamorelin are commonly employed in controlled in vivo and in vitro research settings to assess their pharmacokinetics, efficacy, and safety profiles under experimental conditions. The combination of these agents may provide complementary benefits, such as enhanced GH release while mitigating potential somatostatin-mediated suppression.

Key Research Focus Areas

• Growth Hormone Regulation: Investigating the mechanisms by which CJC-1295 and Ipamorelin modulate GH secretion, including their differential effects on receptor subtypes and signaling pathways.
• Tissue Regeneration: Exploring potential applications in wound healing, muscle repair, and organ regeneration research.
• Metabolic Studies: Evaluating impacts on glucose metabolism, lipid profiles, and overall metabolic homeostasis in experimental models.
• Age-Related Research: Studying the effects of peptide-induced GH release on aging-related declines in growth hormone function and associated physiological changes.
• Pharmacokinetics and Safety: Conducting preclinical assessments of peptide stability, metabolism, and potential off-target effects under controlled research conditions.

Important Compliance Notice

This product is intended solely for use in accredited academic, government, and pharmaceutical research institutions. It is strictly forbidden to use CJC-1295 with Ipamorelin (10 mg) for human or animal consumption, cosmetic purposes, or any therapeutic application. Unauthorized distribution or use is a violation of applicable laws and regulations. Always adhere to the highest ethical and safety standards during research activities.

For research use only. Not for human or animal consumption.